Acasti Pharma Cmn A (ACST) 1.55 $ACST Acasti Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acasti Pharma Cmn A (ACST) 1.55 $ACST

Acasti Announces Grant of Stock Options
Marketwire Canada - Mon May 30, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces the grant of 310,400 stock options under its Stock Option Plan to its employees, including 200,000 to the Chairman of the Board and 61,400 to the officers. Each option will vest gradually over a period of 3 years (1/3 per year) and will allow its holder to acquire one class A common share of the Company at a price of $1.99 until May 29, 2023.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

Acasti Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)

Jan D'Alvise Appointed President & CEO of Acasti Pharma
Marketwire Canada - Thu May 12, 7:09AM CDT
Seasoned Executive in Drug Development
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01), APO.VN: 2.090 (-0.010)

Neptune Announces Preliminary Q4 Results
Marketwired - Tue Apr 05, 6:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ: NEPT)(TSX: NTB), announces preliminary selected results for the fourth quarter ended February 29, 2016. All amounts in Canadian dollars. The financial information in this press release excludes Acasti Pharma.
ACST: 1.55 (unch), NTB.TO: 1.43 (+0.02), NEPT: 1.08 (-0.01)

Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements
Marketwired - Fri Mar 25, 1:03PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces that on March 22, 2016, it received a Nasdaq Deficiency Letter (the "Nasdaq Letter" confirming that the Corporation is no longer in compliance with Nasdaq Listing Rule 5605, requiring a company's audit committee to be comprised of at least three independent directors. Following the resignation of several board members on February 29, 2016, Acasti's Audit Committee is currently comprised of two independent directors.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

Acasti Announces Share-for-Debt
Marketwired - Fri Feb 05, 4:31PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), GSK: 45.25 (+0.18), AGN: 254.86 (+1.91), ABUS: 4.17 (+0.08), ACST: 1.55 (unch), ISIS: 57.56 (-0.28), AZN: 33.84 (-0.30), CBAY: 1.85 (-0.04)

Acasti incurs Q3 net loss of CAD2.191m
M2 - Wed Jan 13, 6:07AM CST
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) stated on Tuesday that it recorded a net loss of CAD2.191m for the third quarter ended 30 November 2015.
ACST: 1.55 (unch)

Acasti reports 3Q loss
Automated Insights - Tue Jan 12, 5:24PM CST
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a fiscal third-quarter loss of $1.7 million, after reporting a profit in the same period a year earlier.
ACST: 1.55 (unch)

Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 12, 4:26PM CST
-- Important progress made with FDA on CaPre(R) development pathway
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents" .
ACST: 1.55 (unch), APO.VN: 2.090 (-0.010)

TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 1.55 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 63

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 97

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 36

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 50

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 63

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover AM Best's New Bookstore for Insurance Insights

Updated Category News Views 92

AM Best Unveils Innovative Bookstore for Insurance Readers AM Best recently launched the AM Best’s Bookstore, a unique digital platform designed for those interested in deeper insights into the insurance sector. This bookstore serves as a central hub for information on newly published books that cover a wide range of topics pertinent to the insurance industry....

Continue Reading
Aurora Mobile Hits a Milestone with Strong Q2 Financials

Updated Category News Views 174

Aurora Mobile Reports Impressive Second Quarter Financial Results Aurora Mobile Limited, recognized for its customer engagement and marketing technology services, has revealed its financial metrics for the second quarter of 2025. This quarter has marked a groundbreaking achievement with the company recording its inaugural quarterly net income under U.S. GAAP. Financial...

Continue Reading
Meta Platforms' Competitive Edge in Media and Services Sector

Updated Category News Views 279

Understanding Meta Platforms in its Industry Context In the fast-paced realm of Interactive Media & Services, comprehensive analysis is vital for both investors and market analysts. This article dives into an industry comparison, focusing on Meta Platforms (NASDAQ: META) along with its prominent competitors. By evaluating crucial financial indicators, market standings,...

Continue Reading
Investigation by Rosen Law Firm for Kaspi.kz Investors

Updated Category News Views 88

Rosen Law Firm's Investigation of Kaspi.kz Security Claims The Rosen Law Firm, globally recognized for protecting investor rights, has launched an investigation regarding potential securities claims for shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This investigation stems from serious allegations that Kaspi.kz may have disseminated misleading business...

Continue Reading
Praxis Precision Medicines to Showcase Innovations This Fall

Updated Category News Views 158

Upcoming Investor Conferences for Praxis Precision Medicines Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a dynamic entity in the field of biopharmaceuticals, has an exciting roster of events lined up this fall. The company is dedicated to developing therapies aimed at addressing central nervous system (CNS) disorders that are driven by imbalances in neuronal...

Continue Reading